Inhibrx [INBX] vs Recursion [RXRX] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Inhibrx Inc. wins in 5 metrics, Recursion Pharmaceuticals Inc. wins in 12 metrics, with 0 ties. Recursion Pharmaceuticals Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Inhibrx Inc. | Recursion Pharmaceuticals Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 0.20 | -2.44 | Inhibrx Inc. |
| Price-to-Book Ratio | 218.85 | 1.64 | Recursion Pharmaceuticals Inc. |
| Debt-to-Equity Ratio | 1,338.82 | 6.89 | Recursion Pharmaceuticals Inc. |
| PEG Ratio | -0.01 | 0.04 | Recursion Pharmaceuticals Inc. |
| EV/EBITDA | -13.09 | -2.10 | Recursion Pharmaceuticals Inc. |
| Profit Margin (TTM) | 0.00% | 4.45% | Recursion Pharmaceuticals Inc. |
| Operating Margin (TTM) | -10,386.54% | -328.80% | Recursion Pharmaceuticals Inc. |
| Return on Equity | -197.85% | -59.54% | Recursion Pharmaceuticals Inc. |
| Return on Assets (TTM) | -51.58% | -27.72% | Recursion Pharmaceuticals Inc. |
| Free Cash Flow (TTM) | $-129.83M | $-380.44M | Inhibrx Inc. |
| 1-Year Return | 672.16% | -14.11% | Inhibrx Inc. |
| Price-to-Sales Ratio (TTM) | 1,347.56 | 24.83 | Recursion Pharmaceuticals Inc. |
| Enterprise Value | $1.73B | $1.19B | Inhibrx Inc. |
| EV/Revenue Ratio | 1,334.32 | 15.88 | Recursion Pharmaceuticals Inc. |
| Gross Profit Margin (TTM) | N/A | 59.62% | N/A |
| Revenue per Share (TTM) | $0 | $0 | Recursion Pharmaceuticals Inc. |
| Earnings per Share (Diluted) | $-9.04 | $-1.44 | Recursion Pharmaceuticals Inc. |
| Beta (Stock Volatility) | N/A | 1.01 | N/A |
| Short % of Float | 19.94% | 34.94% | Inhibrx Inc. |
Inhibrx Inc. vs Recursion Pharmaceuticals Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Inhibrx Inc. | 1.70% | -7.55% | -25.58% | 28.10% | 14.78% | 26.89% |
| Recursion Pharmaceuticals Inc. | -3.88% | 9.46% | -1.42% | -1.98% | -25.54% | -17.38% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Inhibrx Inc. | 672.16% | 322.80% | 375.58% | 409.10% | 409.10% | 409.10% |
| Recursion Pharmaceuticals Inc. | -14.11% | -56.38% | -87.80% | -88.53% | -88.53% | -88.53% |
Performance & Financial Health Analysis: Inhibrx Inc. vs Recursion Pharmaceuticals Inc.
| Metric | INBX | RXRX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.75B | $1.85B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 605,183 | 11,402,630 |
| 90 Day Avg. Volume | 361,518 | 12,390,473 |
| Last Close | $95.22 | $3.47 |
| 52 Week Range | $12.80 - $155.29 | $2.77 - $7.18 |
| % from 52W High | -38.68% | -51.67% |
| All-Time High | $155.29 (Apr 22, 2026) | $42.81 (Jul 12, 2021) |
| % from All-Time High | -38.68% | -91.89% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -1.00% | 6.82% |
| Quarterly Earnings Growth | -1.00% | 6.84% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.04% |
| Operating Margin (TTM) | -103.87% | -3.29% |
| Return on Equity (TTM) | -1.98% | -0.60% |
| Debt to Equity (MRQ) | 1,338.82 | 6.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.55 | $2.14 |
| Cash per Share (MRQ) | $8.50 | $1.41 |
| Operating Cash Flow (TTM) | $-129,794,000 | $-371,808,000 |
| Levered Free Cash Flow (TTM) | $-84,456,128 | $-208,521,744 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Inhibrx Inc. vs Recursion Pharmaceuticals Inc.
| Metric | INBX (Apr 24, 2026) | RXRX (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 0.20 | -2.44 |
| Forward P/E | -42.99 | -4.12 |
| PEG Ratio | -0.01 | 0.04 |
| Price to Sales (TTM) | 1,347.56 | 24.83 |
| Price to Book (MRQ) | 218.85 | 1.64 |
| Market Capitalization | ||
| Market Capitalization | $1.75B | $1.85B |
| Enterprise Value | $1.73B | $1.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1,334.32 | 15.88 |
| Enterprise to EBITDA | -13.09 | -2.10 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.01 |
| Book Value per Share (MRQ) | $0.55 | $2.14 |
Financial Statements Comparison: Inhibrx Inc. vs Recursion Pharmaceuticals Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | INBX (2025) | RXRX (2025) |
|---|---|---|
| Revenue/Sales | 1.30M | 74.26M |
| Cost of Goods Sold | N/A | 70.95M |
| COGS % of Revenue | 0.0% | 95.6% |
| Gross Profit | N/A | 3.30M |
| Gross Margin | 0.0% | 4.4% |
| Research & Development | 113.03M | 475.27M |
| Operating Income (EBIT) | -135.03M | -648.13M |
| Operating Margin | -10,386.5% | -872.8% |
| EBITDA | -125.37M | -559.38M |
| EBITDA Margin | -9,644.2% | -753.3% |
| Pre-Tax Income | -140.05M | -644.90M |
| Pre-Tax Income % of Revenue | -10,773.3% | -868.5% |
| Income Tax | 2,000 | -136,000 |
| Income Tax % of Revenue | 0.2% | -0.2% |
| Net Income (Profit) | -140.06M | -644.76M |
| Profit Margin | -10,773.5% | -868.3% |
Balance Sheet & Liquidity Metrics
| Metric | INBX (2025) | RXRX (2025) |
|---|---|---|
| Cash & Equivalents | 124.22M | 743.29M |
| Total Current Assets | 132.83M | 812.85M |
| Total Current Assets % of Revenue | 10,217.8% | 1,094.7% |
| Total Current Liabilities | 33.80M | 147.71M |
| Total Current Liabilities % of Revenue | 2,599.9% | 198.9% |
| Long-Term Debt | 104.69M | 56.21M |
| Long-Term Debt % of Revenue | 8,052.8% | 75.7% |
| Total Shareholders Equity | 7.99M | 1.13B |
| Retained Earnings | -246.19M | -2.08B |
| Retained Earnings % of Revenue | -18,937.5% | -2,795.7% |
| Property, Plant & Equipment | 5.54M | 158.71M |
Cash Flow Statement Comparison
| Metric | INBX (2025) | RXRX (2025) |
|---|---|---|
| Operating Cash Flow | -126.85M | -422.39M |
| Operating Cash Flow % of Revenue | -9,757.3% | -568.8% |
| Capital Expenditures | -28,000 | -6.47M |
| Free Cash Flow | -129.83M | -380.44M |
| FCF Margin | -9,986.5% | -512.3% |
| Debt Repayment | N/A | -8.43M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | INBX | RXRX |
|---|---|---|
| Shares Short | 2.12M | 174.40M |
| Short Ratio | 10.16 | 14.00 |
| Short % of Float | 19.94% | 34.94% |
| Shares Outstanding | 14.58M | 528.18M |
| Float Shares | 7.81M | 510.29M |
| % Held by Insiders | 26.95% | 2.85% |
| % Held by Institutions | 81.73% | 64.60% |
| % Held by Public | -8.68% | 32.55% |
Dividend Analysis & Yield Comparison: Inhibrx Inc. vs Recursion Pharmaceuticals Inc.
| Metric | INBX | RXRX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |